Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Correction to: Scientific Reports 10.1038/s41598-019-42237-3, published online 16 April 2019

The Acknowledgements section of this Article is incomplete.

“Funded by NIH R21 CA184612-01 and Melanoma Research Foundation CDA Grant Award (A.V.). NIH R01 CA204806 (N.L.). We would like to acknowledge the important technical contributions and advice of Kimberlyn Acklin, MS, SCYM(ASCP), at The George Washington University Flow Cytometry Core Facility and Bethany Rentz, RVT, at The George Washington University Office of Animal Research.”

should read:

“Funded by NIH R21 CA184612-01 and Melanoma Research Foundation CDA Grant Award (A.V.), NIH R01 CA204806 (N.L.), Czech Science Foundation (No 15-19640S), the CAS (RVO: 86652036) and the project „BIOCEV” (CZ.1.05/1.1.00/02.0109) from the ERDF (C.B.). We would like to acknowledge the important technical contributions and the advice of Kimberlyn Acklin, MS, SCYM(ASCP), at The George Washington University Flow Cytometry Core Facility and Bethany Rentz, RVT, at The George Washington University Office of Animal Research.”